

Application No. 10/570,346  
AMENDMENT dated May 12, 2008  
Reply to Office Action of February 11, 2008

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listing, of claims in the application:

**Listing of Claims:**

Claim 1. (Withdrawn) An agent for the prevention and/or treatment of Alzheimer's disease containing c-Abl and/or p19<sup>ARF</sup> as (an) active ingredient(s).

Claim 2. (Cancelled)

Claim 3. (Currently Amended) A screening method wherein a candidate drug which inhibits the interaction between AICD (APP intracellular C-terminal domains) and p53 in neurons is selected [[as]] for development of a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

expressing AICD and p53 in the presence of cisplatin to form an AICD/p53 complex in neurons;

a step of culturing the neurons expressing AICD and p53 in which an AICD/p53 complex is formed, together with a candidate drug;

homogenizing the cultured neurons to form a cell lysate;

a step of obtaining bringing the cell lysate in contact with a first antibody selected from an anti-AICD antibody and an anti-p53 antibody, to form, to form a first immune complex which is a complex of AICD or p53 with [[a]] the first antibody selected from an anti-AICD antibody and an anti-p53 antibody, and to form a second immune complex which is a complex of the AICD/p53 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

Application No. 10/570,346  
AMENDMENT dated May 12, 2008  
Reply to Office Action of February 11, 2008

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-p53 antibody[[],] and which is different from the first antibody, to form a third immune complex of the second immune complex with the second antibody; [and]]

a step of detecting and quantifying the presence of a third immune complex which is a complex of the second immune complex with the second antibody using an immunological technique; and

selecting the candidate drug for development of a drug for the prevention and/or treatment of Alzheimer's disease,

wherein the candidate drug is selected, if the quantity of the third immune complex is small compared to the case where the candidate drug is not contained in the culture.

Claim 4. (Withdrawn) An agent for the prevention and/or treatment of Alzheimer's disease containing A1cICD as an active ingredient.

Claim 5. (Withdrawn) An agent for the prevention and/or treatment of Alzheimer's disease containing a peptide which comprises the amino acid sequence set forth in SEQ ID NO: 1 or 2 of the Sequence Listing as an active ingredient.

Claim 6. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

Claim 7. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Fe65 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

Application No. 10/570,346  
AMENDMENT dated May 12, 2008  
Reply to Office Action of February 11, 2008

a step of culturing neurons expressing AICD and Fe65 in which an AICD/Fe65 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Fe65 with a first antibody selected from an anti-AICD antibody and an anti-Fe65 antibody, and a second immune complex which is a complex of the AICD/Fe65 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Fe65 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

Claim 8. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease.

Claim 9. (Withdrawn) A screening method wherein a candidate drug which inhibits the interaction between AICD and Tip60 in neurons is selected as a drug for the prevention and/or treatment of Alzheimer's disease, said screening method comprising:

a step of culturing neurons expressing AICD and Tip60 in which an AICD/Tip60 complex is formed, together with a candidate drug;

a step of obtaining a first immune complex which is a complex of AICD or Tip60 with a first antibody selected from an anti-AICD antibody and an anti-Tip60 antibody, and a second immune complex which is a complex of the AICD/Tip60 complex with the first antibody, by bringing a cell lysate prepared from the cultured neurons in contact with the first antibody;

Application No. 10/570,346  
AMENDMENT dated May 12, 2008  
Reply to Office Action of February 11, 2008

a step of bringing the first and second immune complexes in contact with a second antibody which is selected from an anti-AICD antibody and an anti-Tip60 antibody, and which is different from the first antibody; and

a step of detecting the presence of a third immune complex which is a complex of the second immune complex with the second antibody.

Claim 10. (Withdrawn) A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 3.

Claim 11. (Withdrawn) A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 7.

Claim 12. (Withdrawn) A drug for the prevention and/or treatment of Alzheimer's disease which can be obtained by the screening method according to claim 9.